Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can remote training bring better cancer care to underserved communities?

NCT ID NCT04984551

Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 15, 2026 · Updated 4 times

Summary

This study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and workshops, then measure changes in patients' quality of life and symptom distress. The goal is to see if this model can help expand access to specialty care in rural and underserved communities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ECHO telementoring program
What this could lead to
If successful, this could show that remote training helps doctors in underserved areas provide better palliative care, improving patient quality of life.
What could go wrong
This is a Phase 2 study focused on measuring experiences and satisfaction, not a direct treatment. Results may not apply to all settings or lead to immediate changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 312 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PATIENT: Scheduled to receive treatment at participating primary care practice for advanced cancer * PATIENT: 18 years or older * PATIENT: Willing to be accessible to the research team for follow-up by telephone or in person * PATIENT: Prognosis of at least 1 year as ascertained by the treating physician * PATIENT: Able to read and understand English as assessed by the treating physician * CAREGIVER: Identified or self-identified as primary caregiver of the patient * CAREGIVER: Willing to be accessible to the research team for follow-up by telephone or in person * CAREGIVER: 18 years or older * CAREGIVER: Able to read and understand English as assessed by the treating physician * ECHO PARTICIPANT: Participant must be a health care provider interested to participate in the study for 2 years and understand the protocol and provide consent * ECHO PARTICIPANT: Able to read and understand English as assessed by principal investigator (PI) Exclusion Criteria: * Unable to understand and sign consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced malignant solid neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced malignant solid neoplasm Hematopoietic and lymphoid cell neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.